This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Moxonidine in Indian Patients

This study has been completed.
Information provided by:
Solvay Pharmaceuticals Identifier:
First received: September 9, 2005
Last updated: January 29, 2009
Last verified: January 2009
The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.

Condition Intervention Phase
Hypertension Drug: Moxonidine Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Multi-Center, Force-Titration Study to Evaluate the Efficacy and Safety of Moxonidine in Ambulatory Subjects With Essential Hypertension

Further study details as provided by Solvay Pharmaceuticals:

Primary Outcome Measures:
  • Systolic blood pressure reduction

Secondary Outcome Measures:
  • Piggy-back pharmacoeconomic evaluation; Safety and tolerability

Estimated Enrollment: 100
Study Start Date: July 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


Exclusion Criteria:

Severe concomitant diseases, CHF, secondary hypertension, severe hypertension, significant hepatic disease, unstable angina

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00160277

Site 1
Jubillee Hills Hyderabad, India
Site 2
Mangalore, India
Site 3
New Delhi, India
Sponsors and Collaborators
Solvay Pharmaceuticals
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information Identifier: NCT00160277     History of Changes
Other Study ID Numbers: S220.3.124
Study First Received: September 9, 2005
Last Updated: January 29, 2009

Keywords provided by Solvay Pharmaceuticals:
Efficacy and safety of moxonidine in Indian hypertensives

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents processed this record on September 19, 2017